Program
buagafuran
Also written as “Buagafuran” and “Buagafuran capsules, 15mg/ capsule”.
Its studies are mostly in Generalized Anxiety Disorder, led by Beijing Union Pharmaceutical Factory.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Beijing Union Pharmaceutical Factory | 44 open or running | phase 3since Jan 7, 2024 | Jan 7, 2024 | none ahead |
Also a collaborator on its studies: r-g-pharma-studies-co-ltd.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 7, 2024First studies: 2 phase 3 studies in Generalized Anxiety DisorderFirst studyNCT06243640, NCT06243614
- Feb 26, 20262 phase 1 studiesNCT07457203, NCT07457190
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07457203Drug Drug Interaction (DDI) · China | 1 | Not yet recruiting | May 2026 | 18 |
| NCT07457190Generalized Anxiety Disorder · China | 1 | Not yet recruiting | Aug 2026 | 24 |
| NCT06243640Generalized Anxiety Disorder · China | 3 | Recruiting | Jun 30, 2026 | 504 |
| NCT06243614Generalized Anxiety Disorder · China | 3 | Recruiting | Jun 30, 2026 | 410 |
How it is read
Names in the registry
- “Buagafuran”, 2 entries
- “Buagafuran capsules, 15mg/ capsule”, 2 entries
Conditions, from the studies’ own filings
- Generalized Anxiety Disorder, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.